Contribute Try STAT+ Today

In late 2015, Senator Ted Cruz introduced a bill to make more drugs available to Americans more quickly. Specifically, his idea would have the Food and Drug Administration approve products for which there is an unmet medical need if those drugs or devices were already approved by regulators in other “trusted” countries. To further cut red tape, the FDA would have just 30 days to make a decision.

So far, his bill has gone nowhere. Meanwhile, a new analysis finds the effort may have a limited impact.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Other trusted countries would includes those in Europe that approved thalidomide, for instance? And the result was many deformed babies. While in the U.S. our FDA did not approve it, and the application was only withdrawn after the results in Europe piled up. And how many drugs that were approved in the U.S. have been withdrawn due to adverse consequences…..more than a few. They need to be careful tinkering with the approval process, or else the rest of us will have to pass up all new drugs from now on, out of caution, since the regulators are not going to be as careful, thanks to congresspeople who think they are helping. The drug companies is who they will be helping, not the damaged patients.

Comments are closed.